PMC:7402624 / 40361-40717 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T371","span":{"begin":113,"end":115},"obj":"Body_part"},{"id":"T372","span":{"begin":191,"end":193},"obj":"Body_part"},{"id":"T373","span":{"begin":274,"end":277},"obj":"Body_part"},{"id":"T374","span":{"begin":288,"end":293},"obj":"Body_part"}],"attributes":[{"id":"A371","pred":"fma_id","subj":"T371","obj":"http://purl.org/sig/ont/fma/fma84371"},{"id":"A372","pred":"fma_id","subj":"T372","obj":"http://purl.org/sig/ont/fma/fma84371"},{"id":"A373","pred":"fma_id","subj":"T373","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A374","pred":"fma_id","subj":"T374","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"eatures in Fig. 5G). Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medicat"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1430","span":{"begin":269,"end":273},"obj":"Gene"},{"id":"1431","span":{"begin":282,"end":285},"obj":"Gene"},{"id":"1435","span":{"begin":88,"end":96},"obj":"Species"},{"id":"1436","span":{"begin":166,"end":174},"obj":"Species"},{"id":"1437","span":{"begin":241,"end":249},"obj":"Species"},{"id":"1445","span":{"begin":113,"end":115},"obj":"Chemical"},{"id":"1446","span":{"begin":191,"end":193},"obj":"Chemical"},{"id":"1454","span":{"begin":130,"end":144},"obj":"Disease"}],"attributes":[{"id":"A1430","pred":"tao:has_database_id","subj":"1430","obj":"Gene:952"},{"id":"A1431","pred":"tao:has_database_id","subj":"1431","obj":"Gene:925"},{"id":"A1435","pred":"tao:has_database_id","subj":"1435","obj":"Tax:9606"},{"id":"A1436","pred":"tao:has_database_id","subj":"1436","obj":"Tax:9606"},{"id":"A1437","pred":"tao:has_database_id","subj":"1437","obj":"Tax:9606"},{"id":"A1454","pred":"tao:has_database_id","subj":"1454","obj":"MESH:D006949"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"eatures in Fig. 5G). Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medicat"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T311","span":{"begin":113,"end":115},"obj":"Disease"},{"id":"T312","span":{"begin":130,"end":144},"obj":"Disease"},{"id":"T313","span":{"begin":191,"end":193},"obj":"Disease"}],"attributes":[{"id":"A311","pred":"mondo_id","subj":"T311","obj":"http://purl.obolibrary.org/obo/MONDO_0019035"},{"id":"A312","pred":"mondo_id","subj":"T312","obj":"http://purl.obolibrary.org/obo/MONDO_0021187"},{"id":"A313","pred":"mondo_id","subj":"T313","obj":"http://purl.obolibrary.org/obo/MONDO_0019035"}],"text":"eatures in Fig. 5G). Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medicat"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T680","span":{"begin":269,"end":273},"obj":"http://purl.obolibrary.org/obo/PR_000001408"},{"id":"T681","span":{"begin":282,"end":285},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T682","span":{"begin":286,"end":293},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"eatures in Fig. 5G). Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medicat"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T278","span":{"begin":113,"end":115},"obj":"Chemical"},{"id":"T280","span":{"begin":191,"end":193},"obj":"Chemical"},{"id":"T282","span":{"begin":278,"end":280},"obj":"Chemical"}],"attributes":[{"id":"A278","pred":"chebi_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/CHEBI_53319"},{"id":"A279","pred":"chebi_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/CHEBI_60686"},{"id":"A280","pred":"chebi_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/CHEBI_53319"},{"id":"A281","pred":"chebi_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/CHEBI_60686"},{"id":"A282","pred":"chebi_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"}],"text":"eatures in Fig. 5G). Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medicat"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":130,"end":144},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0003077"}],"text":"eatures in Fig. 5G). Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medicat"}

{"project":"LitCovid-sentences","denotations":[{"id":"T234","span":{"begin":21,"end":236},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"eatures in Fig. 5G). Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medicat"}